Table 1.

Clinical and laboratory characteristics of patients with HBV infection

Patient number	Sex	Age group	Comorbidities	HbsAg (mIU/mL)	HbsAb	HbcAb	HBV-DNA	Biologic therapies	Follow-up duration (weeks)	PASI baseline	PASI at last observation
1	M	40–44	/	256.66	19.19	Negative	Undetectable	Risankizumab	104	16	0
2	M	55–69	DM2, hypertension	Negative	Positive	Positive	Undetectable	Ustekinumab	52	12	5
3	M	65–69	DM2, NASH	Negative	Negative	Positive	Undetectable	Risankizumab	52	10	1
4	M	50–54	HCVab+	Negative	< 1	Positive	Undetectable	Risankizumab	52	15	0
5	M	55–59	Hypertension, NAFLD	Negative	Negative	Positive	Undetectable	Tildrakizumab	52	25.5	0
6	F	55–59	Hypertension	Negative	Negative	Positive	Undetectable	Risankizumab	52	12	0
7	M	50–54	Metabolic syndrome	Positive	Negative	Positive	Undetectable	Risankizumab	52	20	10
8	M	65–69	Previous bladder carcinoma	Negative	Negative	Positive	Undetectable	Etanercept, risankizumab	208	32	0
9	M	55–59	PsA	Negative	Negative	Positive	Undetectable	Adalimumab, ixekizumab	208	18	0
10	M	55–59	/	Negative	Negative	Positive	Undetectable	Secukinumab	104	18	0.3
11	F	65–69	PsA, hypertension	Negative	Negative	Positive	Undetectable	Guselkumab, ixekizumab	52	10	1
12	M	55–59	Hypercholesterolemia	Negative	211	Positive	Undetectable	Tildrakizumab	52	12	0
13	F	70–74	Hypertension	Negative	Positive	Positive	Undetectable	Risankizumab	52	28	0
14	F	55–59	Hypertension, NASH	Negative	Positive	Positive	Undetectable	Risankizumab	88	10	0
15	M	70–74	Hypertension, QuantiFERON positive	Negative	Negative	Positive	Undetectable	Risankizumab	128	15	0
16	M	45–49	Hypertension, OSAS	Negative	Negative	Positive	Undetectable	Ustekinumab, risankizumab	140	17	0
17	M	60–64	/	Negative	Positive	Positive	Undetectable	Secukinumab, brodalumab	128	10	0

HBV hepatitis B virus, HbsAg HBV surface antigen, HbsAb HBV surface antibody, HbcAb HBV core antibody